Copyright
©The Author(s) 2024.
World J Stem Cells. Dec 26, 2024; 16(12): 1012-1021
Published online Dec 26, 2024. doi: 10.4252/wjsc.v16.i12.1012
Published online Dec 26, 2024. doi: 10.4252/wjsc.v16.i12.1012
Table 1 Baseline characteristics
| Characteristics | Value |
| Age (year), mean ± SD | 68.5 ± 1.7 |
| Male/female (n) | 3:1 |
| Underlying disease, n (%) | |
| IgA nephropathy | 3 |
| Non-IgA mesangial proliferative GN | 1 |
| Comorbidity, n (%) | |
| Ischemic heart disease | 0 (0) |
| Stroke | 0 (0) |
| Hypertension | 3 (75.0) |
| Diabetes | 0 (0) |
| Dyslipidemia | 1 (25.0) |
| Smoking habit, n (%) | |
| No | 4 (100.0) |
| Yes | 0 (0) |
| Body mass index (kg/m2), median (IQR) | 20.3 (18.6-22.2) |
| Laboratory valuables, median (IQR) | |
| Blood urea nitrogen (mg/dL) | 36.5 (24.6-53.5) |
| Creatinine (mg/dL) | 2.42 (2.01-2.98) |
| eGFR (mL/min/1.73 m2) | 19.5 (15.1-26.8) |
| Total protein (g/dL), mean ± SD | 6.1 ± 0.2 |
| Albumin (g/dL), mean ± SD | 3.9 ± 0.2 |
| Total cholesterol (mg/dL), | 221.0 (196.5-242.5) |
| Triglyceride (mg/dL) | 113.5 (70.5-177) |
| HDL-cholesterol (mg/dL) | 65.7 (47.2-85.5) |
| LDL-cholesterol (mg/dL) | 118.0 (109-124) |
| Hemoglobin (g/dL) | 12.0 (11.5-14.4) |
| Urinary protein/creatinine ratio (g/gCr) | 0.91 (0.1-1.3) |
| Urinary blood, grade (%) | 1+ (100.0) |
| Urinary 2 microglobulin (g/L) | 1051.5 (183.9-2975.8) |
| Urinary NGAL/creatinine ratio (microgram/gCr) | 17.5 (10.5-28.0) |
| Medication, n (%) | |
| ARB | 4 (100.0) |
| ACEi | 0 (0) |
| SGLT2 inhibitor | 2 (50.0) |
- Citation: Ohtake T, Sato T, Tsukiyama T, Muraoka S, Mitomo A, Maruyama H, Yamano M, Mochida Y, Ishioka K, Oka M, Moriya H, Hidaka S, Masuda H, Asahara T, Kobayashi S. Preliminary evidence of renal function improvement in chronic progressive kidney disease using autologous CD34+ cell therapy: A clinical trial. World J Stem Cells 2024; 16(12): 1012-1021
- URL: https://www.wjgnet.com/1948-0210/full/v16/i12/1012.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v16.i12.1012